- Home
- CANF vs IMRN Comparison
CANF vs IMRN Comparison
Compare CANF & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- IMRN
- Stock Information
- Founded
- CANF 1994
- IMRN 1994
- Country
- CANF Israel
- IMRN Australia
- Employees
- CANF N/A
- IMRN N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- CANF Health Care
- IMRN Health Care
- Exchange
- CANF Nasdaq
- IMRN Nasdaq
- Market Cap
- CANF 9.6M
- IMRN 9.2M
- IPO Year
- CANF N/A
- IMRN N/A
- Fundamental
- Price
- CANF $0.63
- IMRN $1.83
- Analyst Decision
- CANF Strong Buy
- IMRN Strong Buy
- Analyst Count
- CANF 2
- IMRN 1
- Target Price
- CANF $14.00
- IMRN $5.00
- AVG Volume (30 Days)
- CANF 140.0K
- IMRN 53.8K
- Earning Date
- CANF 08-26-2025
- IMRN 08-29-2025
- Dividend Yield
- CANF N/A
- IMRN N/A
- EPS Growth
- CANF N/A
- IMRN N/A
- EPS
- CANF N/A
- IMRN N/A
- Revenue
- CANF $560,000.00
- IMRN $4,777,422.00
- Revenue This Year
- CANF $461.72
- IMRN N/A
- Revenue Next Year
- CANF N/A
- IMRN N/A
- P/E Ratio
- CANF N/A
- IMRN N/A
- Revenue Growth
- CANF N/A
- IMRN 48.63
- 52 Week Low
- CANF $0.63
- IMRN $1.50
- 52 Week High
- CANF $3.12
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- CANF 29.23
- IMRN 55.18
- Support Level
- CANF $0.64
- IMRN $1.73
- Resistance Level
- CANF $0.68
- IMRN $1.88
- Average True Range (ATR)
- CANF 0.03
- IMRN 0.12
- MACD
- CANF 0.01
- IMRN 0.01
- Stochastic Oscillator
- CANF 2.00
- IMRN 64.52
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.